Results 211 to 220 of about 160,542 (279)

Immunotherapy for Upper Tract Urothelial Carcinomas: A 2026 Update. [PDF]

Cancers (Basel)
Giannakodimos I, Ziogou A, Grigoriou F, Evmorfopoulos K, Zachos I, Deligiannis D, Kratiras Z, Tzortzis V, Bamias A, Chrisofos M, Charalampakis N.   +10 more
europepmc   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Dynamic therapeutic response to osimertinib and immunotherapy in an EGFR L747S and L858R co-mutant NSCLC. [PDF]

Oncologist
Tan Y, Wang T, Yu J, Ouyang W.
europepmc   +1 more source

Pembrolizumab-Induced Eruptive Keratoacanthomas Managed With Intralesional Corticosteroids: A Case Report. [PDF]

Cureus
Varghese K, Vetos D, Woods J, Tate J, Wang-Weinman T.   +4 more
europepmc   +1 more source

SUBDUE‐3: SUB‐urothelial DUrvalumab‐89zirconium injEction; a phase 0 biodistribution study protocol

BJU International, EarlyView.
Kevin G. Keane, Richard Gauci, Roslyn J. Francis, Andrew M. Scott, Cynthia Hawks, Andrisha‐Jade Inderjeeth, Ian D. Davis, Jayne Lim, Andrew Redfern, Dickon Hayne   +9 more
wiley   +1 more source

Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan

Cancer Science, EarlyView.
OS (A–D) and PFS (E–H) in patients receiving (A/E) Atezo + CnP, (B/F) Atezo + PP, (C/G) Atezo + bev + CP, and (D/H) Atezo + CEa by age (≥ 70 years and < 70 years). aSaito R, et al. Presented at the 2024 American Society of Clinical Oncology Annual Meeting. Abstract 8092. Adapted with permission by the author.
Junichi Shimizu, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Eisaku Miyauchi, Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Kozo Yoshimori, Kazuhiko Shibata, Takeshi Tsuda, Masahiro Seike, Takahiro Ota, Koichi Samata, Yuki Kobayashi, Misa Tanaka, Akihiko Gemma   +19 more
wiley   +1 more source

Pembrolizumab for MSI-high/TMB-high bone and soft tissue sarcomas: a retrospective single-institution study. [PDF]

Front Oncol
Kawasaki T, Torigoe T, Tsujimoto D, Watanabe T, Hirasaki M, Kamakura Y, Wako M, Mitsui K, Ichikawa J.   +8 more
europepmc   +1 more source

First‐In‐Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck

Cancer Science, EarlyView.
The dose escalation part of the first‐in‐human study of E7130 in patients with advanced solid tumors determined the Recommended Phase 2 Dose of E7130 (480 μg/m2 Q3W). The dose expansion part (presented here) examined safety/preliminary efficacy in patients with squamous cell carcinoma of the head and neck and urothelial carcinoma.
Nobuaki Matsubara, Ken Saijo, Yasushi Shimizu, Susumu Okano, Kenji Nakano, Naoki Nishio, Tomoyuki Otsuka, Hirofumi Kuno, Takuma Miura, Tomoki Kubota, Hiroki Ikezawa, Yuko Umetsu, Ken Ito, Abraham Apfel, Yuanqing Ye, Yoshitaka Honma   +15 more
wiley   +1 more source

Severe immune-related autoimmune hemolytic anemia induced by pembrolizumab: a case report with novel immunosuppressive strategy. [PDF]

Front Immunol
Ye Q, Li M, Zhou P, Huang S, Xie K.
europepmc   +1 more source

Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB–IIIA Non‐Small‐Cell Lung Cancer: Phase 2 neoSCORE Trial

Cancer Science, EarlyView.
Kaplan–Meier survival curves comparing two‐cycle versus three‐cycle neoadjuvant sintilimab plus chemotherapy. (A) Disease‐free survival (DFS). (B) Overall survival (OS). CI, confidence interval; HR, hazard ratio; NR, not reached. ABSTRACT The optimal number of neoadjuvant chemoimmunotherapy cycles for resectable non‐small cell lung cancer (NSCLC ...
Miner Shao, Jie Yao, Lufeng Zhao, Ling Zhu, Baizhou Li, Lili Li, Bangyi Zhou, Yixin Zhang, Huiying Liu, Xiaoke Chen, Zuqun Wu, Zexin Chen, Junqiang Fan, Fuming Qiu   +13 more
wiley   +1 more source